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Key Points Summary 58 
 Voltage-gated sodium channels play a fundamental role in determining neuronal 59 
excitability 60 
 Specifically, voltage-gated sodium channel subtype NaV1.7 is required for sensing 61 
acute and inflammatory somatic pain in mice and humans but its significance in 62 
pain originating from the viscera is unknown. 63 
 Using comparative behavioural models evoking somatic and visceral pain 64 
pathways, we identify the requirement for NaV1.7 in regulating somatic (noxious 65 
heat pain threshold) but not in visceral pain signalling.  66 
 These results enable us to better understand the mechanisms underlying the 67 
transduction of noxious stimuli from the viscera, suggest that the investigation of 68 
pain pathways should be undertaken in a modality-specific manner and help to 69 
direct drug discovery efforts towards novel visceral analgesics. 70 
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Abstract 71 
Voltage-gated sodium channel NaV1.7 is required for acute and inflammatory pain in mice and 72 
humans but its significance for visceral pain is unknown. Here we examine the role of NaV1.7 in 73 
visceral pain processing and the development of referred hyperalgesia using a conditional 74 
nociceptor-specific NaV1.7 knockout mouse (NaV1.7Nav1.8) and selective small-molecule NaV1.7 75 
antagonist PF-5198007. NaV1.7Nav1.8 mice showed normal nociceptive behaviors to intracolonic 76 
application of either capsaicin or mustard oil, stimuli known to evoke sustained nociceptor 77 
activity and sensitization following tissue damage, respectively. Normal responses following 78 
induction of cystitis by cyclophosphamide were also observed in both NaV1.7Nav1.8 and littermate 79 
controls. Loss, or blockade, of NaV1.7 did not affect afferent responses to noxious mechanical 80 
and chemical stimuli in nerve-gut preparations in mouse, or following antagonism of NaV1.7 in 81 
resected human appendix stimulated by noxious distending pressures. However, expression 82 
analysis of voltage-gated sodium channel α subunits revealed NaV1.7 mRNA transcripts in 83 
nearly all retrogradely-labelled colonic neurons suggesting redundancy in function. By contrast, 84 
using comparative somatic behavioral models we identify that genetic deletion of NaV1.7 (in 85 
NaV1.8-expressing neurons) regulates noxious heat pain threshold and that this can be 86 
recapitulated by the selective NaV1.7 antagonist PF-5198007. Our data demonstrates that 87 
NaV1.7 (in NaV1.8-expressing neurons) contributes to defined pain pathways in a modality-88 
dependent manner, modulating somatic noxious heat pain but is not required for visceral pain 89 
processing, and advocates that pharmacological block of NaV1.7 alone in the viscera may be 90 
insufficient in targeting chronic visceral pain. 91 
 92 
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Abbreviations 93 
BSA Bovine serum albumin 
CIP Congenital insensitivity to pain 
CT Quantification cycles 
DRG Dorsal root ganglia 
FB Fast Blue 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
IC/BPS Interstitial cystitis/bladder pain syndrome 
LS Lumbosacral 
NaV Voltage-gated sodium channel 
PEPD Paroxysmal extreme pain disorder 
PO Per os 
QST Quantitative standardized testing 
TL Thoracolumbar 
TRPV1 Transient receptor potential cation channel V1 
TTX-R Tetrodotoxin-resistant 
TTX-S Tetrodotoxin-sensitive 
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Introduction  95 
Chronic pain originating from internal organs affects significant proportions of the population 96 
with analgesics restricted by dose-limiting side-effects. Persistent pain and visceral 97 
hypersensitivity manifests as reduced thresholds for mechanical distension of visceral organs 98 
and are strongly associated with inflammation. The targeting of peripheral sensory input, either 99 
by peripheral nerve block (Cherry et al., 1985; Brown, 1989; Eisenberg et al., 1995) or local 100 
anaesthetics (Verne et al., 2003; Verne et al., 2005) has proven effective in treating visceral pain. 101 
However, our understanding of key sensory afferent transduction mechanisms responsible for 102 
visceral nociception is limited. Here, we investigate voltage-gated sodium channel NaV1.7 in 103 
both visceral and somatic pain behaviors and show that peripheral pain pathways of the viscera 104 
are functionally distinct from classical nociceptors, providing evidence supporting functional 105 
diversity of nociception and confirmation that novel analgesic development must be applied in a 106 
mechanism-specific manner. 107 
Rare human genetic conditions link NaV1.7 to pain perception, with loss-of-function mutations 108 
causing congenital insensitivity to pain (CIP) (Cox et al., 2006; Goldberg et al., 2007). 109 
Recapitulation of the human painless phenotype using knockout mice genetically engineered to 110 
globally lack NaV1.7 results in complete loss of responses to acute, inflammatory and 111 
neuropathic pain (Gingras et al., 2014). Using tissue-specific NaV1.7 knockout mice (including 112 
nociceptor-specific NaV1.7Nav1.8 mice (Nassar et al., 2004), pan-sensory neuron NaV1.7Advill mice 113 
(Minett et al., 2012) and pan-sensory and sympathetic neuron NaV1.7Wnt1 mice (Minett et al., 114 
2012)) modality-specific pain pathways associated with acute heat and mechanical detection, 115 
hyperalgesia and allodynia have been linked with differing NaV repertoires.  116 
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Intriguingly, CIP patients feel no visceral pain with reports of both painless childbirth and 117 
rupture of appendix (Melzack & Wall, 1988; Zimmermann et al., 1988; Wheeler, 2015), 118 
suggesting that NaV1.7 may be required for visceral nociception. Rectal pain is a symptom of 119 
paroxysmal extreme pain disorder (PEPD), another condition associated with rare NaV1.7 120 
mutations (Fertleman et al., 2006), with defecation capable of triggering pain attacks 121 
implicating a link to anorectal distension. In patients with interstitial cystitis/bladder pain 122 
syndrome (IC/BPS), pain perception associates with NaV1.7 mutations (Reeder et al., 2013). 123 
Like other chronic pain conditions, a hallmark of IC/BPS is ongoing pain in the absence of 124 
obvious pathophysiology (Dimitrakov & Guthrie, 2009). Therefore NaV1.7 could be involved in 125 
maintaining spontaneous pain, such as peripheral or central sensitization, in addition to evoked 126 
pain attributed to mechanical stimulation. Surprisingly, whilst broad-spectrum sodium channel 127 
blockers are effective in treating chronic visceral pain, selective NaV1.7 antagonists (ProTx-II) 128 
and monoclonal blocking antibodies targeting NaV1.7 have been unable to fully recapitulate loss 129 
of NaV1.7 mutant phenotypes to other chronic pain models (Schmalhofer et al., 2008; Lee et al., 130 
2014). Indeed, selective antagonism of NaV1.7 with ProTx-II also failed to block afferent 131 
responses to stretch of the colorectum (Feng et al., 2015), suggesting the contribution of NaV1.7 132 
to visceral pain processing is still unclear.  133 
In light of recent findings that NaV1.7 is essential for some (acute heat and mechanical pain, 134 
inflammatory hyperalgesia and neuropathic allodynia), but not all (acute cold pain, cancer-135 
induced bone pain and oxaliplatin-evoked allodynia) pain modalities, we investigated visceral 136 
pain and referred hyperalgesia using a conditional nociceptor-specific NaV1.7 knockout mouse 137 
(NaV1.7Nav1.8) and selective NaV1.7 antagonist PF-5198007. Thus, using comparative behavioral 138 
models evoking somatic and visceral pain pathways we identify specific mechanisms regulating 139 
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noxious heat pain threshold and show that NaV1.7 in NaV1.8-expressing neurons is not required 140 
for visceral pain signalling.  141 
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Materials and Methods 142 
Experiments were performed in adult mice weighing 20 – 35 g. Conditional nociceptor-specific 143 
NaV1.7 knockout mice (NaV1.7Nav1.8) and their littermate controls were generated as described 144 
previously (Nassar et al., 2004). Observers performing behavioral and ex vivo 145 
electrophysiological experiments were blind to the genotypes of the animals. Animals were 146 
acclimatized for at least one week before behavioral testing in temperature and light-controlled 147 
(12hr light/dark cycle) rooms. All experiments were performed in accordance with the UK 148 
Animals (Scientific Procedures) Act of 1986 or with the EU Directive 2010/63/EU for animal 149 
experimentation, with approval of the University of Granada Research Ethics Committee (Granada, 150 
Spain). Human tissues were collected and utilised with approval of the East London and The City 151 
HA Local Research Ethics Committee (London, UK; NREC 10/H0703/71) in accordance with the 152 
Declaration of Helsinki and following full written informed consent.  153 
Behavioral experiments  154 
Experiments were performed on both male and female knockout and wild-type littermate 155 
control mice. Visceral pain and referred hyperalgesia was assessed using previously described 156 
methods, with small modifications (Olivar & Laird, 1999; Laird et al., 2001; Gonzalez-Cano et al., 157 
2013). Briefly, mice were acclimatized for 40 minutes to test chambers (consisting of a 158 
transparent box on an elevated wire mesh floor) after which 50μl of capsaicin (0.1 or 1%), 159 
mustard oil (0.01 or 0.1%) or vehicle was instilled intrarectally via a thin cannula inserted into 160 
the anus and the animal returned to the chamber. The number of spontaneous pain behaviors 161 
(including licking of abdomen, stretching of abdomen and abdominal retractions) were 162 
recorded for the subsequent 20 minutes. In a separate set of experiments, visceral pain 163 
behaviors caused by cyclophosphamide-induced cystitis were examined following a previously 164 
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described protocol (Olivar & Laird, 1999). Again after a 40 min habituation, animals were 165 
removed from the test chamber and cyclophosphamide (100 or 200mg/kg) or vehicle injected 166 
intraperitoneally. The animals were returned to the chamber and pain behaviors recorded 167 
according to the following scale: 0 = normal, 1 = piloerection, 2 = strong piloerection, 3 = 168 
labored breathing, 4 = licking of the abdomen and 5 = stretching and contraction of the 169 
abdomen. If more than one of these behaviors was noted during a single observation period, 170 
then only the type and not quantity of each different pain behavior was scored (i.e. if two 171 
stretching and contractions (5 points) and one abdominal licking (4 points) was observed, then 172 
a score of 9 was assigned).  173 
After the evaluation of spontaneous pain behaviors (primary behavioral endpoint), the presence 174 
of referred hyperalgesia was determined by measuring the withdrawal response to a punctate 175 
mechanical stimulation (von Frey hair filaments 0.02 – 2 g (0.19-19.6 mN), Touch-Test Sensory 176 
Evaluators, North Coast Medical Inc., USA) of the abdomen using the up-down paradigm 20 177 
minutes after algogen administration (Chaplan et al., 1994). Avoiding the perianal and external 178 
genitalia, the mid-range 0.4 g von Frey hair filament was applied (three times for 2-3 sec at 5 sec 179 
intervals) to the lower and mid abdomen. If a positive response (consisting of immediate 180 
licking/scratching of the application site, sharp retraction of the abdomen or jumping) was 181 
observed, then probing was repeated in consecutive tests with a weaker von Frey filament. By 182 
contrast if there was no response to probing then a stronger von Frey filament was used. Once 183 
the withdrawal threshold (secondary behavioral endpoint) was ascertained, mice were 184 
humanely killed by concussion of the brain and cervical dislocation of the neck.  185 
Electrophysiological recordings of visceral afferent activity 186 
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Nerves innervating murine and human gastrointestinal tissues were isolated and 187 
electrophysiological activity recorded using previously described methods (Peiris et al., 2011; 188 
Hockley et al., 2014). Mice were humanely killed by concussion of the brain and cervical 189 
dislocation of the neck. The distal colon with associated lumbar splanchnic nerves was removed 190 
and transferred to a recording chamber superfused (7 ml/min; 32-34 oC) with carbogenated 191 
Krebs buffer (in mM: 124 NaCl, 4.8 KCl, 1.3 NaH2PO4, 2.5 CaCl2, 1.2 MgSO4.7H2O, 11.1 glucose, 192 
and 25 NaHCO3) supplemented with nifedipine (10 µM), atropine (10μM) and indomethacin (3 193 
µM). The same supplemented Krebs buffer was used to luminally perfuse (100 µl/min) the 194 
colon after cannulation.  195 
To translate murine experimental recordings into human tissue, we recorded extrinsic nerve 196 
activity from resected human appendices. We have previously shown that the appendix 197 
represents a valid human ex vivo model of visceral afferent activity amenable to the testing of 198 
mechanical and chemical stimuli (Peiris et al., 2011). Specifically, the extrinsic nerves of the 199 
appendix are a branch of those innervating the right colon along the ileocolic artery and 200 
represent a readily available tissue in normal non-inflamed (e.g. from colon cancer resections) 201 
states. Resected appendices were obtained from 5 patients undergoing elective surgery at Barts 202 
Health NHS Trust, London after full written consent was attained. Appendices were removed 203 
from patients undergoing right hemicolectomies as part of their normal surgical treatment for 204 
bowel cancer or slow transit constipation (see Table 1 for details) with the permission of the 205 
histopathologist and were returned to the morbid anatomy department after completion of the 206 
studies. Once removed, appendix specimens were immediately placed in cold Krebs buffer and 207 
handled in a comparable manner to mouse distal colon tissues. Removal of the tip and 208 
cannulation enabled intraluminal perfusion, in addition to superfusion with Krebs buffer (7 209 
mL/min; 32-34 oC) supplemented with 10 µM nifedipine and 10 µM atropine. Under a dissection 210 
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microscope, mesenteric neurovascular bundles were blunt dissected and associated nerves 211 
identified and cleared of connective tissue. Using borosilicate glass suction electrodes, multi-212 
unit activity from whole lumbar splanchnic nerves (rostral to the inferior mesenteric ganglia) of 213 
mouse, or from mesenteric nerves of human bowel tissues, was recorded. Signals were 214 
amplified and band pass filtered (gain 5 K; 100-1300 Hz; Neurolog, Digitimer Ltd, UK) and 215 
digitized at 20 kHz (micro1401; Cambridge Electronic Design, UK) before display on a PC using 216 
Spike 2 software. The signal was digitally filtered for 50 Hz noise (Humbug, Quest Scientific, 217 
Canada) and a threshold of twice the background noise (typically 100 µV) was used to 218 
determine action potential firing counts.  219 
Electrophysiological protocols 220 
Following a stabilizing period of 30 minutes, noxious intraluminal distending pressures were 221 
applied by blocking the luminal perfusion out-flow of the cannulated mouse distal colon or 222 
resected human appendix. The noxious pressures reached evoke pain behaviors in vivo and are 223 
above threshold for all known visceral afferent mechanoreceptors (Ness & Gebhart, 1988; 224 
Hughes et al., 2009). In murine experiments, a combined sequential protocol was used to 225 
initially assess multiple aspects of visceral afferent mechanosensitivity and chemosensitivity. 226 
Specifically, a set of 6 rapid phasic distensions (0-80 mm Hg, 60 s at 9 min intervals) followed by 227 
slow ramp distension (0-145 mmHg, ~5-6 min) were implemented prior to bath superfusion of 228 
separate 20 ml volumes of 1 μM bradykinin and 1mM ATP at 40 min intervals. In separate 229 
experiments, the effect of pharmacological inhibition of NaV1.7 on visceral afferent sensitivity to 230 
mechanical distension or noxious stimulation by capsaicin, mustard oil or bradykinin was 231 
tested. A set of 9 rapid phasic distensions (0-80 mm Hg, 60 s at 9 min intervals) followed by a 30 232 
min stabilization period and bath superfusion of 1 μM bradykinin in a 20 ml volume were 233 
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performed. Prior to the 7th phasic distension, bath superfusion of the selective NaV1.7 antagonist 234 
PF-5198007 (100 nM; 500 mL; (Alexandrou et al., 2016)) or vehicle (0.1 % DMSO) was initiated 235 
and maintained for the duration of the remaining three distensions and bradykinin application. 236 
In some experiments, after a wash-out period, repeat phasic distensions were performed during 237 
which 250 ml tetrodotoxin (TTX; 100 nM) was superfused. In separate experiments, a ramp 238 
distension (0-145mmHg) was performed followed by bath superfusion of capsaicin (500nM) 239 
and mustard oil (250 μM) at 1 hour interval. Five minutes prior to application of capsaicin, 240 
either 100nM PF-5198007 or vehicle (0.1% DMSO) was applied for the duration of the 241 
subsequent stimulations. Human appendix specimens were stimulated in a comparable manner 242 
by repeat ramp distension (0-60 mm Hg, ~30 s at 9 min intervals). Baseline responses were 243 
established for three distensions prior to the superfusion of PF-5198007 (100 nM or 1 μM) for 244 
50 min during subsequent distensions.  245 
Retrograde labelling of gut-specific sensory neurons and single-cell qRT-PCR 246 
Distal colon-specific sensory neurons were retrogradely labelled, picked and the expression of 247 
mRNA transcripts of interest determined by qRT-PCR. A mid-line 1.5cm laparotomy was 248 
performed on male mice after induction of anaesthesia with 1.5% isoflurane. Multiple injections 249 
of Fast Blue (FB: 0.2 μl per site, 2% in saline, Polysciences Gmbh, Germany) were made using a 250 
fine pulled-glass needle and microinfusion pump (0.4 μl/min) into the wall of the distal colon. 251 
Prior to suturing of the peritoneal muscle layer and securing the skin with Michel clips, the 252 
abdominal cavity was flushed with saline to remove any excess FB. Post-operative care 253 
(monitoring body weight and soft diet) and analgesia (buprenorphine 0.05-0.1 mg/kg daily) 254 
was provided for the duration of the protocol. Three to five days after surgery, mice were 255 
humanely killed by concussion of the brain and cervical dislocation of the neck, and 256 
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thoracolumbar (TL: T10-L1) and lumbosacral (LS: L5-S2) dorsal root ganglia (DRGs) were 257 
harvested and cultured separately for gene expression experiments. Dissected ganglia were 258 
incubated at 37°C (in 5% CO2) in Lebovitz L-15 Glutamax (GIBCO, UK) media containing 1mg/ml 259 
collagenase type 1A (Sigma) and 6mg/ml bovine serum albumin (BSA; Sigma, UK) for 15 min, 260 
followed by L-15 media containing 1mg/ml trypsin (Sigma, UK) and 6mg/ml BSA for 30 min. 261 
Ganglia were gently triturated and collected by brief centrifugation at 500 g. The supernatant 262 
(containing dissociated cells) was collected and the cycle of gentle trituration and centrifugation 263 
repeated. Cells from TL and LS DRG were plated separately onto poly-D-lysine–coated 264 
coverslips (BD Biosciences, UK) and incubated in Lebovitz L-15 Glutamax media containing 2 % 265 
penicillin/streptomycin, 24 mM NaHCO3, 38mM glucose and 10 % fetal bovine serum. Fast Blue 266 
positive colonic sensory neurons were individually harvested from cultures of retrogradely 267 
labelled DRG (either TL: T10-L1 or LS: L5-S2) by pulled glass pipette. By breaking the pipette tip 268 
(containing the cell) into a tube containing preamplification mastermix (2.5μl 0.2x 269 
primer/probe mix, 5μl CellDirect 2x reaction buffer (Invitrogen), 0.1 μl SUPERase-in (Ambion, 270 
TX, USA), 1.2 μl TE buffer (Applichem, Germany) and 0.2 μl Superscript III Reverse 271 
Transcriptase/Platinum Taq mix (Invitrogen)) and freezing immediately, mRNA transcripts 272 
were preserved. Only those individual Fast Blue positive neurons free from debris and other 273 
non-neuronal cells (e.g. satellite glia) were collected. An image of each harvested neuron was 274 
also captured using a camera (DCC1545M, ThorLabs Inc, NJ, USA) attached to the inverted 275 
microscope enabling an estimation of cell size to be ascertained. In the absence of cells, samples 276 
of the bath solution were collected for no-template control experiments. Using the following 277 
thermal cycling protocol, preamplification of cDNA was achieved: 50°C for 30 minutes, 95°C for 278 
2 minutes, then 21 cycles of (95°C for 15 seconds, 60°C for 4 minutes). After dilution (1:5 TE 279 
buffer), Taqman qPCR assays were run for each gene of interest (Taqman Assay ID: NaV1.1, 280 
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Mm00450580_m1; NaV1.2, Mm01270359_m1; NaV1.3, Mm00658167_m1; NaV1.4, 281 
Mm00500103_m1; NaV1.5, Mm01342518_m1; NaV1.6, Mm00488110_m1; NaV1.7, 282 
Mm00450762_s1; NaV1.8, Mm00501467_m1; NaV1.9, Mm00449367_m1; GAPDH, 283 
Mm99999915_g1; Applied Biosystems) using the following cycling protocol: 50°C for 2 minutes, 284 
95°C for 10 minutes, then 40 cycles of (95°C for 15 seconds, 60°C for 1 minutes). 285 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) acted as an internal positive control, 286 
with all single-cell RT-PCR products expressing GAPDH and bath control samples were negative 287 
for all Taqman reactions. Relative expression of NaVs was normalized to GAPDH quantification 288 
cycles (CT) using 2-CT formula. Quantitative assessment of gene expression was determined by 289 
quantification cycle values less than the threshold of 35 being considered as positive.  290 
Ramping hotplate pain behaviors  291 
Behavioral phenotyping experiments were performed using both male and female mice, and 292 
pharmacology experiments were carried out in male mice. Acute heat pain was assessed using a 293 
ramping hotplate comparable to that used in human standardised quantitative testing (QST) 294 
protocols (Rolke et al., 2006). Mice were acclimatized in a chamber for 6 minutes daily for the 3 295 
days preceding dosing. After which, following a 30 second acclimatization, the chamber floor 296 
was slowly heated from 31°C at a rate of 3.4°C/min and the temperature and time taken until 297 
observing a pain behavior was recorded (behavioral endpoint; the occurrence of either licking 298 
or shaking of the hind paw and/or rapid shifting of weight (stomping) from one foot to the 299 
other). After baseline measurements were made, mice were dosed via oral administration (P.O.) 300 
with either vehicle or PF-5198007 at 1 or 3mg/ml with a dose volume of 10ml/kg and 1hr later, 301 
the ramping hotplate repeated. Mice were humanely killed by concussion of the brain and 302 
cervical dislocation of the neck immediately after final assessment of thermal pain threshold. 303 
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Skin-nerve preparation 304 
Multi-unit extracellular afferent recordings were made from the tibial nerve innervating the 305 
glaborous skin of the hind paw as previously described (Milenkovic et al., 2008) but with some 306 
modifications. Briefly, mice were humanely killed by concussion of the brain and cervical 307 
dislocation of the neck, the hind limbs were then shaved, removed and the tibial nerve and 308 
associated glaborous skin dissected free. The preparation was mounted glaborous skin 309 
downwards in a recording chamber superfused (10ml/min; 36±1˚C) with carbogenated (95% 310 
O2, 5% CO2) Krebs buffer (in mM: NaCl 107, KCl 3.48, NaHCO3 26.2, MgSO4(.7H2O) 0.69, NaH2PO4 311 
1.67, Na-gluconate 9.64, sucrose 7.6, glucose 5.5, CaCl 1.53). The epiperineurium was removed 312 
from the distal end of the tibial nerve and suction electrode recordings comparable to those of 313 
visceral afferent activity were made. Following a 60 minute stabilisation period, a heat stimulus 314 
(Krebs perfused onto the skin at a focal point equivalent to the heel portion of the paw) lasting 315 
50 seconds was applied, this increased in temperature from 36˚C to 52˚C at a rate of 316 
0.4˚C/second to mimic the noxious heat ramp used in vivo. In total, a series of 10 heat 317 
stimulations were performed at 15 minutes intervals. The first 4 heat stimulation formed the 318 
baseline reading with bath superfusion of PF-5198007 (30nM) or vehicle (0.1% DMSO) initiated 319 
and maintained for the duration of the next 2 stimulations (30 minutes), PF-5198007 (100nM) 320 
or vehicle (0.1% DMSO) for the following 2 heat stimulations (30 minutes) and heat 321 
stimulations 9 and 10 carried out during the superfusion (15 minutes) of TTX (100nM or 322 
300nM) and lidocaine (1mM), respectively. In separate experiments, the effect of genotype and 323 
selective sodium channel antagonists were assessed in response to a cold stimulus (36 to 6˚C at 324 
a rate of 0.4˚C/second) delivered in the same manner as the heat stimulus, with comparable 325 
stimulation and protocols as above. 326 
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Data analysis 327 
Pain behaviors and mechanical thresholds were compared across experimental groups with 2-328 
way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test, using either 329 
SigmaPlot 12.0 (Systat Software Inc., CA, USA) or Prism 6 (GraphPad Inc., USA). Referred 330 
hyperalgesia, expressed as the mechanical threshold producing 50% of responses, was 331 
calculated using: 50% mechanical threshold (g)  [(10 (Xf + κδ)) /10], where Xf  value (in 332 
logarithmic units) of the final von Frey filament used; κ  tabular value for the pattern of 333 
positive/negative responses; and δ  mean difference (in log units) between stimuli (Dixon, 334 
1980). Peak changes or total sum firing of electrophysiological nerve activity in multi-unit 335 
experiments were determined by subtracting baseline firing (2 minutes before distension or 336 
drug application) from increases in nerve activity following distension or noxious chemical 337 
superfusion. Estimation of cell size from single-cell images was achieved by averaging the height 338 
and width of each cell (ImageJ 1.49V analysis software, NIH, USA). Total sum firing of 339 
electrophysiological nerve activity in response to each hot or cold stimulation was obtained by 340 
subtracting any signal evoked by heat/cold stimulation in the presence of lidocaine (1mM). 341 
Expression data was visualized using R and the ggplot2 graphics package (Wickham, 2009). 342 
Statistical significance was set at P < 0.05. Data are displayed as mean ± SEM. 343 
Drugs 344 
Stock concentrations of capsaicin (1%; 10% ethanol, 10% tween, 80% saline), mustard oil (1%; 345 
70% ethanol, 30% saline), cyclophosphamide (saline), bradykinin (10mM; water), lidocaine 346 
(1M; water) and ATP (300mM; water) were purchased from Sigma-Aldrich and prepared as 347 
described. Tetrodotoxin (15μg/ml stock) was purchased from Nanning Leaf Pharmaceuticals 348 
(Canada) and diluted in saline. PF-5198007 was manufactured in-house by Pfizer and 349 
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solubilized in DMSO at a 10mM stock. For in vitro experiments, PF-5198007 was applied at a 350 
concentration of 100nM (ensuring almost 100% inhibition of mouse NaV1.7 (IC50 5.2nM) and 351 
selectivity over NaV1.1 and NaV1.6 (IC50 149nM and 174nM, respectively)(Alexandrou et al., 352 
2016)). For in vivo studies PF-5198007, 1mg/ml or 3mg/ml, was suspended in 0.5% 353 
methylcellulose + 0.1% Tween-80 in distilled water. Doses of PF-5198007 were selected to 354 
achieve a free plasma concentration of ~100nM (littermate: 1mg/kg, 58 ± 10 nM, N = 5; 355 
3mg/kg, 842 ± 91 nM, N = 10; NaV1.7Nav1.8: 1mg/kg, 68 ± 12 nM, N = 5; 3mg/kg, 634 ± 69 nM, N = 356 
9). Vehicle was dosed as a 10ml/kg solution of 0.5% methylcellulose + 0.1% Tween-80 in 357 
distilled water. All other compounds were diluted in appropriate experimental buffer to 358 
working concentrations on the day of experimentation, unless otherwise stated.  359 
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Results 360 
Visceral pain behaviors to colorectal sensitizing noxious stimuli were unaffected by 361 
deletion of NaV1.7  362 
We used a conditional NaV1.7 knockout mouse strain, where floxed (SCN9A) NaV1.7 mice were 363 
crossed with mice in which Cre expression is driven by the NaV1.8 promotor (NaV1.7Nav1.8) 364 
resulting in tissue-specific ablation of NaV1.7 in sensory neurons expressing nociceptive 365 
markers (Nassar et al., 2004; Shields et al., 2012). Capsaicin acts at TRPV1 and will activate the 366 
vast majority of visceral afferent terminals (>85% (Christianson et al., 2006; Malin et al., 2009)) 367 
leading to neurogenic inflammation and prolonged ongoing afferent activity due to sensitization 368 
(Laird et al., 2001; Laird et al., 2002). Intracolonic instillation of capsaicin in littermate control 369 
mice led to dose-dependent increases in observed pain behaviors consisting of abdominal 370 
contractions and licking (Fig. 1A). The deletion of NaV1.7 from NaV1.8-positive neurons, 371 
however, did not attenuate pain behaviors at either dose of capsaicin tested (P = 0.72, N = 6-8, 372 
2-way ANOVA). In separate experiments, the potent algogen mustard oil was instilled 373 
intracolonically leading to the activation and sensitization of afferents and induction of localized 374 
tissue damage as previously described (Laird et al., 2002). Substantial pain behaviors were 375 
observed in both NaV1.7Nav1.8 and littermate controls (Fig. 1B), which were not significantly 376 
different in terms of the magnitude of their response (P = 0.79, N = 6-8, 2-way ANOVA). The 377 
time course of pain behaviours induced by capsaicin and mustard oil did not differ between 378 
littermate controls and NaV1.7Nav1.8 mice. These findings show that NaV1.7 expressed in NaV1.8-379 
positive neurons is not required for the development of visceral pain or for sustained 380 
spontaneous nociceptor activity as a result of sensitization.  381 
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Referred hyperalgesia is a common characteristic of visceral pain, with the sensitization of 382 
somatic structures in the same metameric field to the affected organ driven in part by spinal 383 
convergence of somatic and visceral afferents inputs (Cervero, 1983; Mertz et al., 1995). Whilst 384 
primary inflammatory hyperalgesia has been shown to be dependent on NaV1.7 in NaV1.8-385 
expressing neurons, whether NaV1.7 contributes to the development of secondary hyperalgesia 386 
remains unstudied. The development of mechanical sensitivity of the abdomen in response to 387 
intracolonic instillation of either capsaicin (0.1%) or mustard oil (0.01%) was independent of 388 
ablation of NaV1.7 from NaV1.8-expressing neurons, with 50% withdrawal thresholds 389 
significantly reduced 20 minutes after treatment irrespective of genotype (capsaicin; P < 0.01, N 390 
= 6-8, 2-way ANOVA; mustard oil, P < 0.01, N = 6-8, 2-way ANOVA).  391 
Pain responses to cyclophosphamide-induced cystitis are unaffected by deletion of 392 
NaV1.7 393 
To model bladder pain/cystitis in NaV1.7Nav1.8 mice, cyclophosphamide was administered 394 
leading to the progressive development of visceral pain behaviors for the duration of the 4 hour 395 
observation window. Cyclophosphamide treatment produces mucosal erosion and 396 
haemorrhage of the bladder in addition to edema (Fraiser et al., 1991). The development and 397 
time course of pain behaviors observed did not differ between littermate controls and 398 
NaV1.7Nav1.8 mice to either dose of cyclophosphamide tested (Fig. 2A, P = 0.93, N = 6-8, 2-way 399 
ANOVA). Indeed both NaV1.7Nav1.8 mice and littermate controls also showed marked referred 400 
hyperalgesia when tested 4 hours after cyclophosphamide treatment (Fig. 2B). The referred 401 
hyperalgesia did not differ dependent on genotype suggesting that persistent activation of 402 
nociceptors by a developing noxious chemical stimuli is not driven by a requirement for NaV1.7 403 
to be present. 404 
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Visceral afferent mechanosensitivity is blocked by TTX but is unaffected by deletion of 405 
NaV1.7 or blockade with a selective small-molecule NaV1.7 antagonist 406 
In order to distinguish between the multiple roles that NaV1.7 makes to nociceptive processing, 407 
we investigated the contribution of NaV1.7 to mechanosensitivity and chemosensitivity at the 408 
peripheral terminals of sensory neurons innervating the gastrointestinal tract. To do this multi-409 
unit ex vivo extracellular electrophysiological recordings of lumbar splanchnic nerve activity 410 
were made from the distal colon of mice. Tissues were dissected free and cannulated to enable 411 
mechanical and chemical stimuli to be applied by luminal distension or bath superfusion. Phasic 412 
distension of the colon to noxious pressures (0-80 mm Hg) was used to model mechanical 413 
stimulation of the bowel and evoke increased afferent firing for the duration (60 second) of the 414 
distension. Consistent with previous reports, adaptation in the response to repeat stimulation 415 
(at 9 minute intervals) was observed during subsequent distensions with the response 416 
stabilizing by the fourth to sixth distension (see Fig. 3A & C) (Hockley et al., 2014). In 417 
NaV1.7Nav1.8 mice, there was no significant difference in either the initial peak distension 418 
response or in the degree of tachyphylaxis observed during repeat distensions compared to 419 
littermate controls (Fig. 3C, P = 0.62, N = 13-14, 2-way repeated-measures (RM) ANOVA). 420 
Previous studies have suggested that not only the magnitude, but also the dynamic quality, of 421 
the distension paradigm used may be important for delineating gut motor events, specifically 422 
noxious stimuli (Sengupta & Gebhart, 1994; Booth et al., 2008). Given the proposed role of 423 
NaV1.7 as a threshold channel contributing to the amplification of depolarizing stimuli in 424 
sensory neurons (Dib-Hajj et al., 2013), we used a slow ramp distension protocol to 425 
supramaximal distension pressures (0-145 mm Hg) in order to investigate the impact of loss of 426 
NaV1.7 on responses across a range of innocuous and noxious distending pressures. In 427 
littermate controls, afferent firing increased proportionally to intraluminal pressure with a peak 428 
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firing rate of 37.5 ± 5.7 spikes/s at 145 mm Hg. Significantly less firing was observed in 429 
NaV1.7Nav1.8 mice to equivalent distending pressures (at 145 mm Hg, 25.7 ± 4.2 spikes/s; P < 430 
0.0001, N = 19, 2-way ANOVA). However, firing rates in NaV1.7Nav1.8 mice to ramp distension 431 
were unchanged within the physiologically-relevant 0-80 mm Hg range compared to controls (P 432 
> 0.05, Bonferroni’s post-hoc analysis). Within the supramaximal range (80 -145 mm Hg), there 433 
was a reduction in firing, suggesting NaV1.7 may be involved in transducing non-physiological 434 
extremes of pressure in the colon but not innocuous or even noxious mechanical stimuli.  435 
Given that NaV1.7 is ablated only in NaV1.8-positive neurons, it is possible that visceral afferents 436 
that are both sensitive to noxious mechanical stimuli and are negative for NaV1.8 may be 437 
contributory to the responses observed. In order to test this hypothesis, in a further set of 438 
experiments, repeat phasic distensions were continued and the effect of the selective small-439 
molecule NaV1.7 antagonist PF-5198007 (100nM) was assessed on responses in both 440 
NaV1.7Nav1.8 and littermate control mice. Responses in littermate control mice to repeat phasic 441 
distensions were unchanged following pre-incubation with, and in the presence of, 100nM PF-442 
5198007 compared to vehicle (Fig. 3E, P = 0.86, N = 7, 2-way RM ANOVA). Further, the afferent 443 
response following application of 100nM PF-5198007 in NaV1.7Nav1.8 mice also did not 444 
significantly differ from that observed in wild-type animals (P = 0.87, N = 6-7, 2-way RM 445 
ANOVA). However, irrespective of genotype, application of 100nM TTX to preparations did fully 446 
block afferent firing to noxious phasic distension (Fig. 3E). Together this shows that 447 
mechanosensitivity in visceral afferents is dependent on TTX-sensitive voltage-gated sodium 448 
channels but not NaV1.7. 449 
Loss, or antagonism, of NaV1.7 does not alter visceral afferent responses to acute 450 
inflammatory and algogenic mediators 451 
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To investigate the involvement of NaV1.7 in modulating visceral afferent sensitivity to 452 
inflammatory and algogenic mediators used in our in vivo studies, capsaicin and mustard oil 453 
were applied to distal colon preparations and visceral afferent responses recorded from both 454 
littermate and NaV1.7Nav1.8 mice, and in the presence or absence of 100nM PF-5198007. In 455 
separate experiments, bradykinin and ATP, as inflammatory mediators typically present during 456 
injury or infection, and that may be evoked by mustard oil/cyclophosphamide treatment 457 
contributing to ongoing nociceptor sensitization were also tested.  458 
Responses to application of 500nM capsaicin did not differ between NaV1.7Nav1.8 mice and 459 
littermate mice in vehicle control experiments (0.1% DMSO; NaV1.7Nav1.8 vs. littermate; P = 0.50, 460 
N = 6 both groups, unpaired t-test, Fig. 4A). In addition, superfusion of 100nM PF-5198007 461 
during, and 5 minutes prior to, capsaicin (500nM) application did not significantly change the 462 
evoked afferent discharge in either genotype (NaV1.7Nav1.8: 100nM PF-5198007 vs. 0.1% DMSO, 463 
P = 0.82, N = 6, unpaired t-test; littermate: 100nM PF-5198007 vs. 0.1% DMSO, P = 0.59, N = 6, 464 
unpaired t-test, Fig. 4A). Afferent firing evoked by mustard oil was also unchanged in both 465 
NaV1.7Nav1.8 mice and littermate controls (0.1% DMSO: NaV1.7Nav1.8 vs. littermate, P = 0.46, N = 6, 466 
unpaired t-test, Fig. 4B), irrespective of the presence of NaV1.7 antagonist (NaV1.7Nav1.8: 100nM 467 
PF-5198007 vs. 0.1% DMSO, P = 0.44, N = 6, unpaired t-test; littermate: 100nM PF-5198007 vs. 468 
0.1% DMSO, P = 0.93, N = 6, unpaired t-test, Fig. 4B). 469 
Bath superfusion of 1mM ATP in littermate mice resulted in significant afferent discharge with a 470 
peak change in firing of 1.39 ± 0.50 spikes/s. In NaV1.7Nav1.8 mice, the response was comparable 471 
to littermate controls (2.33 ± 0.80 spikes/s, P = 0.32, N = 7-8, unpaired t-test). Responses to 472 
application of 1μM bradykinin were greater than that observed for ATP, however did not differ 473 
dependent on genotype (littermate, 9.11 ± 3.32 vs. NaV1.7Nav1.8, 8.56 ± 3.04 spikes/s, P = 0.90, N 474 
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= 7-8, unpaired t-test). Further, in distal colon preparations from littermate controls pre-475 
incubated with 100nM PF-5198007, peak firing response to 1μM bradykinin was unchanged 476 
(vehicle (0.1% DMSO) 5.16 ± 2.00 versus 100nM PF-5198007 4.31 ± 0.63 spikes/s, P = 0.70, N = 477 
7, unpaired t-test); this was also true of tissues from NaV1.7Nav1.8 mice pre-incubated with the 478 
NaV1.7 antagonist (100nM PF-5198007; P = 0.17, N = 6-7, unpaired t-test). Collectively, these 479 
data suggest that NaV1.7 within the peripheral terminal of colonic sensory neurons is not 480 
required in order to transduce both noxious mechanical and chemical algogenic stimuli, in 481 
agreement with behavioral experiments. 482 
Localization of NaV expression in colonic sensory neurons 483 
We next investigated the expression of voltage-gated sodium channel α subunits present in 484 
colonic sensory neurons. Specifically, using single-cell qRT-PCR we examined the expression of 485 
mRNA transcripts for NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8 and NaV1.9 486 
in gut-projecting sensory neurons. Both lumbar splanchnic and pelvic innervation have been 487 
shown to contribute to the transmission of noxious stimuli from the distal colon (Brierley et al., 488 
2004). As such, the expression of these channels was determined in colonic sensory neurons in 489 
dorsal root ganglia (DRG) T10 to L1 levels (thoracolumbar: TL) that are known to possess the 490 
greatest number of sensory neurons projecting via the lumbar splanchnic nerve, and separately 491 
in DRG L5 to S2 levels (lumbosacral: LS); the afferents from which have been shown to project 492 
predominantly via the pelvic nerve. Of the 30 cells collected per mouse (N = 3), the average size 493 
of colonic sensory neurons harvested was 32.0 ± 0.2 μm for TL (N = 3) and 30.7 ± 1.0 μm for LS 494 
(N = 3). In the NaV1.7Nav1.8 mice used in the studies described here, NaV1.7 was selectively 495 
ablated from all NaV1.8-positive sensory neurons. To confirm the proportion of colonic sensory 496 
neurons affected by this gene ablation, the expression of NaV1.7 and NaV1.8 was first examined. 497 
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NaV1.7 was present in 100% of thoracolumbar and 95.6 ± 2.22% of lumbosacral colonic sensory 498 
neurons. High expression of NaV1.8 was also observed in both thoracolumbar (95.6 ± 2.22 %) 499 
and lumbosacral (91.1 ± 4.44 %) colonic sensory neuron populations. Importantly, significant 500 
co-expression of both these sodium channels in individual colonic sensory neurons was found, 501 
with 95.4% of NaV1.7-positive neurons also expressing NaV1.8, suggesting that the vast majority 502 
of colonic sensory neurons in NaV1.7Nav1.8 mice would be affected by the genetic deletion. 503 
The expression of the remaining tetrodotoxin-sensitive (TTX-S: NaV1.1, NaV1.2, NaV1.3, NaV1.4 504 
and NaV1.6) and TTX-resistant voltage-gated sodium channels (TTX-R: NaV1.5 and NaV1.9) was 505 
also determined (Catterall et al., 2005). Of the TTX-S sodium channels, NaV1.6 was present in the 506 
greatest frequency (86.7%; Fig. 5A) of thoracolumbar colonic sensory neurons after NaV1.7. 507 
Significant proportions of thoracolumbar colonic sensory neurons also expressed either NaV1.1 508 
(44.4 ± 5.88 %), NaV1.2 (68.9 ± 8.89 %) or NaV1.3 (53.3 ± 10.2 %), although co-expression was 509 
not always observed (see Fig. 5C). As expected, both the skeletal myocyte voltage-gated sodium 510 
channel NaV1.4 and the cardiac myocyte NaV1.5 channel were expressed by low proportions of 511 
thoracolumbar colonic sensory neurons (6.67 ± 6.67 % and 17.8 ± 5.88 %, respectively). In 512 
agreement with previous studies, mRNA transcripts for TTX-R NaV1.9 were observed in 84.4 ± 513 
44.4 % of thoracolumbar neurons (Hockley et al., 2016). By comparison, the expression of 514 
NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.7 and NaV1.8 did not significantly differ between 515 
populations of lumbosacral compared to thoracolumbar colonic sensory neurons (Fig. 5A, all P > 516 
0.05, TL vs. LS, unpaired t-test). Interestingly, significant differences were observed between the 517 
frequency of expression of NaV1.5 (TL vs. LS, P < 0.05, unpaired t-test) and NaV1.6 (TL vs. LS, P < 518 
0.01, unpaired t-test) in lumbosacral compared to thoracolumbar colonic sensory neurons. 519 
Indeed, transcripts for both NaV1.5 and NaV1.6 were observed in approximately half of 520 
lumbosacral colonic sensory neurons (48.9 ± 8.01 % and 51.1 ± 5.88 %, respectively). The 521 
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expression of NaV1.9 (which has been shown previously to contribute to afferent sensitivity of 522 
the lumbar splanchnic nerve(Hockley et al., 2014)) in lumbosacral colonic sensory neurons 523 
were consistent with the frequency of expression observed in the thoracolumbar populations (P 524 
= 0.42, N = 3, unpaired t-test). Taken together, these data not only support the expression of 525 
NaV1.7 by a majority of colonic sensory neurons innervating the distal colon, but also highlight 526 
an as yet unexplored complexity in the molecular patterning of voltage-gated sodium channels 527 
present in these neurons.  528 
Deletion of NaV1.7 impairs somatic noxious thermal thresholds, which can be 529 
recapitulated by NaV1.7 antagonism 530 
Given that no differences in acute visceral pain or referred hyperalgesia could be observed in 531 
mice lacking NaV1.7 in NaV1.8-positive neurons or to block of NaV1.7 by the selective inhibitor 532 
PF-5198007, we next sought to investigate the role of NaV1.7 in somatic acute pain behaviors. In 533 
order to investigate the contribution of NaV1.7 in NaV1.8-positive sensory neurons to the 534 
modulation of thermal thresholds, we utilized a ramping hotplate behavioral paradigm. In 535 
littermate controls, this latency was 261 ± 5 seconds (N = 38) corresponding to a temperature 536 
rise of ~13.6°C (baseline floor temperature 31°C ramping to 44.6 ± 0.2°C; Fig. 6A). This increase 537 
in temperature required to evoke a behavioral response was equivalent to a previous study 538 
using a modified ramping Hargreaves’ test (Minett et al., 2014a). NaV1.7Nav1.8 mice showed an 539 
attenuated response to ramping hotplate with an augmented latency (274 ± 5 s) and 540 
significantly increased thermal threshold (46.1 ± 0.3°C, N = 36, P < 0.0001, unpaired t-test; Fig. 541 
6A) in agreement with previous observations (Minett et al., 2014a). The attenuation of complex 542 
behaviors associated with the ramping hotplate test suggests involvement of NaV1.7 in pain 543 
signalling to noxious thermal stimulation of the skin under certain conditions.  544 
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Using the ramping hotplate, we went on to confirm the ability for the selective NaV1.7 inhibitor 545 
PF-5198007 to modulate thermal pain behaviors (see Fig. 6B). In littermate mice, application of 546 
PF-5198007 (1mg/kg P.O.) significantly increased the thermal threshold for observing pain 547 
behaviors with a concomitant increase in the latency to response when compared to vehicle 548 
controls (P < 0.01, N = 10, 2-way ANOVA with Bonferroni’s post-hoc vs. vehicle; Fig. 6B). In both 549 
vehicle and PF-5198007 treatment groups, the thermal threshold of NaV1.7Nav1.8 mice remained 550 
significantly greater than littermate controls but did not differ between groups. Application of a 551 
higher dose of PF-5198007 (3mg/kg P.O.) also led to an increase in thermal threshold during 552 
hotplate ramp, which was comparable to thresholds observed in NaV1.7Nav1.8 mice and 553 
significantly different from vehicle groups (P < 0.05, N = 10, 2-way ANOVA with Bonferroni’s 554 
post-hoc vs. vehicle). These data suggest that whilst pain behaviors can be evoked in the 555 
absence, or antagonism, of NaV1.7, the expression of NaV1.7 in sensory neurons modulates heat 556 
pain thresholds to noxious thermal stimuli. 557 
NaV1.7 also contributes to cutaneous afferent firing to both noxious hot, but not cold, 558 
thermal stimuli 559 
To investigate whether NaV1.7 was necessary for sensory transduction at the peripheral 560 
terminal of somatic afferents, ex vivo multi-unit electrophysiological recordings of the tibial 561 
nerve from skin-nerve preparations of NaV1.7Nav1.8 mice and littermate controls were made (Fig. 562 
6C & D). In support of hotplate experiments, a ramping thermal stimuli (focal water jet from 563 
36°C to 52°C (at ~0.4°C/sec)) was applied to the corium side of the skin and the evoked nerve 564 
activity recorded. Total firing during the heat-evoked stimuli was significantly attenuated in 565 
NaV1.7Nav1.8 mice compared to littermate controls (Fig. 6E, P < 0.0001, N = 26-29, 2-way ANOVA 566 
with Bonferroni’s post-hoc). Bath superfusion of 100nM TTX led to significant inhibition of 567 
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firing regardless of genotype compared to vehicle controls (Fig. 6E, P < 0.05, N = 9-11 and P < 568 
0.0001, N = 10-11, NaV1.7Nav1.8 and littermate controls, respectively, 2-way ANOVA with 569 
Bonferroni’s post-hoc), suggesting that the transduction of noxious thermal stimuli at the 570 
peripheral terminal of sensory afferents is enhanced by the presence of NaV1.7 in NaV1.8-571 
positive neurons, but is dependent on other TTX-S NaVs that might be present. Application of 572 
100nM PF-5198007 in littermate controls was able to recapitulate the attenuated response 573 
observed in NaV1.7Nav1.8 mice (Fig. 6F, P < 0.05, N = 9-10, 2-way ANOVA with Bonferroni’s post-574 
hoc vs. vehicle (0.1% DMSO)). In addition, PF-5198007 in NaV1.7Nav1.8 mice further reduced 575 
afferent responses to heat ramp suggesting that afferent firing at the peripheral terminal is 576 
dependent predominantly on expression of NaV1.7 in NaV1.8-positive sensory neurons. 577 
However, this does not discount contributions of NaV1.7 to other sensory populations spinally 578 
or supra-spinally involved in the nociceptive processing of thermal stimuli.  579 
In addition, we investigated cutaneous afferent firing to evoked cold stimuli by localized 580 
perfusion of a cooling perfusate over the receptive field from 36°C to ~6°C (at ~0.4°C/sec). In 581 
previous studies, NaV1.7 has been shown to be involved in acetone-induced cooling, but not 582 
noxious cold sensation (Minett et al., 2012). Responses evoked by cold stimulation of the skin 583 
did not differ between NaV1.7Nav1.8 mice and littermate controls (Fig. 6G, P > 0.05, N = 18, 2-way 584 
ANOVA with Bonferroni’s post-hoc), however application of 100nM TTX completely abolished 585 
cold-evoked responses compared to vehicle (P < 0.01, N = 6 and P < 0.0001, N = 5-6, littermate 586 
and NaV1.7Nav1.8 mice, respectively, 2-way ANOVA with Bonferroni’s post-hoc). Finally 587 
incubation with the selective NaV1.7 antagonist PF-5198007 (100nM) did not significantly 588 
attenuate cold evoked afferent firing (Fig. 6H), supporting the posit that NaV1.7 does not 589 
contribute to the transduction or amplification of cold-evoked depolarizations at the peripheral 590 
terminal. 591 
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Mesenteric nerve responses to phasic distension in human appendix are unaffected by 592 
inhibition of NaV1.7 593 
Finally, in order to understand whether our findings in murine visceral afferents translate to 594 
human we used ex vivo extracellular recordings of surgically resected appendices to investigate 595 
NaV1.7 function in response to mechanical stimuli. The human appendix has been used 596 
previously as a pre-clinical model of visceral nociception (Peiris et al., 2011). The appendix was 597 
cannulated and stimulated by repeat noxious ramp distension (0-60 mm Hg) and mesenteric 598 
nerve firing recorded. Ramp distension evoked a concomitant increase in human visceral 599 
afferent firing with a peak change in firing of 10.1 ± 1.5 spikes/s (N = 5), with reproducible 600 
responses observed to subsequent distensions. Application of PF-5198007 did not significantly 601 
impair visceral afferent firing to ramp distension at either low or high distending pressures (Fig. 602 
7B, P = 0.26, N = 5, 2-way RM ANOVA). This confirms our mouse data highlighting that NaV1.7 603 
appears not to significantly impact visceral afferent sensitivity to acute mechanosensation. As 604 
such, NaV1.7 imparts functionality on sensory neurons in a modality-specific manner and 605 
therefore the analgesic assessment of NaV1.7 antagonists should be determined in a mechanism-606 
dependent fashion.      607 
 608 
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Discussion 609 
Nociceptive processing in somatic and visceral pain has common underlying pathways, 610 
including convergence in neuroanatomy, overlap in psychological representation and 611 
commonality in cellular transductions. However, important differences exist in the 612 
manifestation, perception and psychology of these pain modalities. Traditionally, visceral 613 
afferents are characterized based on mechanical sensitivity and activation by chemical 614 
mediators (including bradykinin and ATP (Su & Gebhart, 1998; Brierley et al., 2004; Grundy, 615 
2004)), with functional assessment required to define nociceptive properties. Compared to 616 
somatic counterparts, visceral sensory neurons almost exclusively possess characteristics 617 
attributed to nociceptors (unmyelinated C-fibres (Sengupta & Gebhart, 1994), peptidergic 618 
(Robinson et al., 2004) and high expression of NaV1.8/TTX-R sodium currents (Beyak et al., 619 
2004)), yet collectively transduce innocuous unconscious and conscious sensations in addition 620 
to pain. As such, visceral sensory neurons do not fit well with classical views of nociceptors and 621 
established schema for nociceptive transduction pathways.   622 
Here, we add to this by showing that visceral pain signalling in vivo to acute and sensitizing 623 
noxious stimuli is independent of NaV1.7. We confirm by way of ex vivo electrophysiological 624 
recordings of mouse visceral afferent fibres that deletion of, or selective small-molecule 625 
antagonism of NaV1.7, does not attenuate responses to persistent noxious mechanical (including 626 
repeat phasic and sustained ramp distension) and chemical stimuli (including capsaicin, 627 
mustard oil, bradykinin and ATP). This lack of efficacy in NaV1.7 antagonism in blocking visceral 628 
afferent activation extends to recordings from resected human appendix tissues when applying 629 
noxious distending pressures. Surprisingly, mouse visceral sensory neurons almost always 630 
express NaV1.7 suggesting that, whilst present, NaV1.7 appears not to contribute to the 631 
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modulation of afferent excitability to depolarizing stimuli, or the propagation of action 632 
potentials. Furthermore, the lack of phenotype observed in NaV1.7Nav1.8 mice suggests NaV1.7 is 633 
not necessary for transducing noxious visceral input centrally by NaV1.8-expressing neurons. By 634 
contrast somatically, deletion of NaV1.7 does modulate acute heat pain thresholds, which can be 635 
replicated using selective NaV1.7 antagonism. Strikingly, loss of NaV1.7 from NaV1.8-expressing 636 
neurons, or small-molecule antagonism, are able to attenuate afferent firing evoked by ramping 637 
heat stimuli applied to skin-nerve preparations. This implicates NaV1.7 in modulating thermal 638 
transduction sensitivity in somatic afferents. This was not true of cold stimuli, where NaV1.7 639 
does not have a role in afferent responses. Our data demonstrates that whilst NaV1.7 does 640 
modulate defined somatic pain pathways, it is not required for those visceral pain modalities 641 
investigated here and advocates that selective pharmacological block of NaV1.7 in the viscera 642 
may prove ineffective in targeting chronic visceral pain caused by spontaneous nociceptor 643 
activity, sensitizing inflammatory mediators or evoked mechanical distension: principal clinical 644 
drivers of visceral pain. 645 
Voltage-gated sodium channels are vital for the transmission of painful stimuli in primary 646 
afferents. Importantly, the relative significance of individual sodium channels is dependent on 647 
the pain modality considered, with NaV1.7 essential in transducing somatic acute thermal and 648 
mechanical pain, in conjunction to inflammatory hyperalgesia and neuropathic allodynia 649 
(Minett et al., 2014b). Similarly, NaV1.8 is critical for extreme cold pain (Abrahamsen et al., 650 
2008), with chemotherapy-induced allodynia dependent on NaV1.6 (Sittl et al., 2012; Deuis et al., 651 
2013). Normal visceral nociceptor activity, by contrast, is dependent on both NaV1.8 (Laird et al., 652 
2002) and NaV1.9 (Hockley et al., 2014). Surprisingly, the role of NaV1.7 in visceral pain 653 
processing is poorly understood in spite of human genetic data linking NaV1.7 to pain signalling.  654 
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Substantive evidence for the involvement of NaV1.7 in visceral pain processing comes from 655 
human genetic studies. Patients with congenital insensitivity to pain linked to mutations in 656 
NaV1.7 do not feel pain, including pain originating from internal structures (broken bones (Cox 657 
et al., 2006; Goldberg et al., 2007)) and hollow organs (e.g. during appendicitis or child-birth 658 
(Melzack & Wall, 1988; Zimmermann et al., 1988)). Mutations in SCN9A gene encoding NaV1.7 659 
are also causal in paroxysmal extreme pain disorder (PEPD) where severe burning pain may 660 
occur in rectal, ocular and mandibular regions. Intriguingly, defecation and micturition can both 661 
trigger such rectal pain attacks (Fertleman et al., 2006; Meglic et al., 2014), implicating 662 
hypersensitivity of visceral mechanoreceptors in initiating pain attacks. Whilst NaV1.7 is linked 663 
with multiple aspects of the pain pathway, this is the first report detailing the contribution of 664 
NaV1.7 to visceral pain processing. Using single-cell qRT-PCR of gut-specific sensory neurons we 665 
show that mRNA transcripts for NaV1.7 are expressed by the vast majority of colonic sensory 666 
neurons, consistent with NaV1.7 immunoreactivity in extrinsic afferent terminals of the distal 667 
colorectum (Feng et al., 2015). Co-expression of NaV1.7 in NaV1.8-positive neurons was 668 
substantial in gut-projecting populations, suggesting that nearly all visceral sensory neurons 669 
would be affected by NaV1.8-specific knockout of NaV1.7 (Nassar et al., 2004). However, it is 670 
possible that some NaV1.7-positive NaV1.8-negative colonic neurones remain, which may be 671 
sufficient to maintain pain behaviours. 672 
Visceral afferent firing to mechanical and chemical activation were unaffected following loss of, 673 
or antagonism of, NaV1.7, but could be blocked by TTX as shown previously (Campaniello et al., 674 
2016). As such, TTX-S NaVs other than NaV1.7 are involved in transducing noxious visceral 675 
stimuli. Established roles for TTX-R NaV1.8 and NaV1.9 correlate well with their extensive 676 
expression shown here; however little is known about the expression of TTX-S NaVs within a 677 
viscerally-projecting population. NaV1.6 is essential in pelvic afferent endings for spike initiation 678 
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and repetitive firing (Feng et al., 2015), a concept that would fit with the extensive presence of 679 
NaV1.6 mRNA transcripts observed here. Further, using toxin antagonists of NaV1.7 (ProTx-II) 680 
and NaV1.6 (μ-conotoxin GIIIa and μ-conotoxin PIIIa), a requirement on NaV1.6, but not NaV1.7, 681 
was observed for the encoding of stretch-sensitive pelvic afferents (Feng et al., 2015). Taken 682 
together, these observations present compelling evidence that NaV1.7 is redundant in visceral 683 
afferent nociception to spontaneous or evoked noxious stimuli.  684 
Clearly whilst not necessary for normal sensation in the gut, the high relative expression of 685 
NaV1.7 suggests that aberrant NaV1.7 function, such as that present in some monogenic pain 686 
disorders, could significantly impact visceral sensation. Intriguingly, the propensity for 687 
mutations in NaV1.7 to evoke regional pain phenotypes in PEPD patients (i.e. rectal and not ‘true 688 
visceral’ pain) could be driven by differences we observe here in the expression of some sodium 689 
channels (NaV1.5(Renganathan et al., 2002) and NaV1.6(Cummins et al., 2005)) located in 690 
thoracolumbar, versus lumbosacral, visceral sensory neurons. Precedent for background 691 
neuronal phenotype contributing to the manifestation of functional effects already exists with 692 
the same mutation in NaV1.7 causing hypo- and hyper-excitability when expressed in either 693 
sympathetic or sensory neurons (Rush et al., 2006). The extensive expression of NaV1.7 suggests 694 
that mutations subverting its endogenous function may significantly alter phenotype even if not 695 
required for that pain modality normally. As such it is possible that non-canonical roles of 696 
NaV1.7 may help explain the contradiction of how CIP patients associated with loss of NaV1.7 do 697 
not feel visceral pain. For example, recent evidence of NaV1.7 deletion upregulating endogenous 698 
opioid expression suggests a complex transcriptional modulatory, as well as electrogenic, 699 
contribution by NaV1.7, however this did not alter the expression of other NaV subtypes present 700 
in DRG (Minett et al., 2015). Importantly, the use of a selective small-molecule antagonist of 701 
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NaV1.7 enables us to discount developmental differences in gene deletion studies in the 702 
phenotypes observed here. 703 
Comparison with somatic pain behaviors enables confirmation of a modality-specific action for 704 
NaV1.7 expression and confirms the ability of the antagonist PF-5198007 in replicating gene 705 
deletion studies. NaV1.7 is required for modulating heat pain thresholds after burn injury 706 
(Shields et al., 2012) and for acute noxious heat sensing in a population of NaV1.8-negative 707 
neurons (Minett et al., 2012). Surprisingly, we found using an adapted ramping hotplate test 708 
that loss of NaV1.7 from NaV1.8-positive neurons could also alter acute heat pain thresholds and 709 
this could be recapitulated using PF-5198007. In all cases, mice remained sensitive to noxious 710 
heat, suggesting that NaV1.7 is not required in NaV1.8-expressing neurons but can modulate the 711 
thermal threshold sensitivity. Notably, we observed a desensitization of the heat pain threshold 712 
from ~44°C by 2-3°C following antagonism of NaV1.7, as such fixed temperature hotplate tests 713 
typically used to measure withdrawal latencies at 50°C or 55°C would be above threshold in 714 
either case masking potential phenotypic differences. A similar non-redundant role for NaV1.7 in 715 
NaV1.8-expressing neurons was observed to an adapted Hargreaves’ test (Minett et al., 2014a). 716 
This further highlights the involvement of multiple sub-populations of neurons on stimulus-717 
intensity specific responses underpinning noxious thermal detection. 718 
In summary, using a combination of gene deletion knockout mice and pharmacological tool 719 
molecule we demonstrate that NaV1.7, although expressed extensively by gut-projecting sensory 720 
neurons, contributes minimally to visceral pain pathways associated with algogenic sensitizing 721 
chemicals and evoked activation of visceral afferents by noxious stimuli. The patterning of 722 
sodium channel expression shown here reveals a previously unstudied molecular complexity to 723 
visceral sensory neurons. Combined with a detailed study of somatic thermal sensitivity, we 724 
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show that assessment of candidate analgesic targets to pain mechanisms must be considered in 725 
a modality-specific manner. As such, NaV1.7 antagonism of peripheral visceral afferents may not 726 
represent a viable therapeutic rationale for the treatment of chronic visceral pain associated 727 
with evoked distension or inflammation of the viscera.  728 
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Figure Legends 729 
Figure 1. Spontaneous visceral-pain related behaviors in NaV1.7Nav1.8 and littermate mice 730 
following intracolonic administration of capsaicin (A and C) or mustard oil (B and D). Number of 731 
acute pain related behaviors (licking of abdomen, stretching, abdominal retractions) induced by 732 
capsaicin (A) or mustard oil (B) during a 20 min period. Referred mechanical hyperalgesia 733 
(evaluated by stimulation of the abdomen with von Frey filaments) was measured 20 min after 734 
the administration of capsaicin (C) or mustard oil (D). Mean ± SEM of values obtained in 6-10 735 
animals. *P < 0.05 and **P < 0.01 vs. vehicle. 736 
 737 
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Figure 2. Visceral pain related behaviors evoked by cyclophosphamide-induced cystitis in 738 
NaV1.7Nav1.8 and littermate mice. (A) Behavioral pain responses were recorded at 30 minute 739 
intervals during the 240 min observation period after cyclophosphamide injection. (B) Referred 740 
mechanical hyperalgesia was evaluated by stimulation of the abdomen with von Frey filament 741 
4h after cyclophosphamide administration. Mean ± SEM of values obtained in 6-10 animals. *P < 742 
0.05 and **P < 0.01, vs. vehicle. 743 
 744 
Figure 3. Visceral afferent responses to noxious distension of the distal colon in NaV1.7Nav1.8 mice 745 
and following small-molecule NaV1.7 antagonism. Example rate histogram of colonic splanchnic 746 
nerve activity and intraluminal pressure trace to repeat phasic distension (0-80 mm Hg; 60 s; 9 747 
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min intervals) in NaV1.7Nav1.8 (B) and littermate (A) mice. (C) Peak change in firing rate during 748 
phasic distensions in both genotypes (P = 0.46, 2-way repeated-measures ANOVA). (D) Average 749 
firing rates to ramp distension (0-145 mm Hg) at 5 mm Hg increments in littermate and 750 
NaV1.7Nav1.8 mice. (E) Effect of 100nM PF-5198007, vehicle (0.1% DMSO) or 100nM TTX on total 751 
firing evoked during repeat 0-80 mm Hg phasic distensions in littermate and NaV1.7Nav1.8 mice.  752 
 753 
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Figure 4. Effect of capsaicin and mustard oil on visceral afferent responses. Change in peak firing 754 
rate to application of 500nM capsaicin (A) and 250μM mustard oil (B) in littermate and 755 
NaV1.7Nav1.8 mice, both in the absence and presence of 100nM PF-5198007.  756 
 757 
Figure 5. Expression of voltage-gated sodium channel mRNA transcripts in mouse colonic 758 
sensory neurons by single-cell qRT-PCR. (A) Proportions of thoracolumbar and lumbosacral 759 
colonic sensory neurons expressing transcripts for NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, 760 
NaV1.6, NaV1.7, NaV1.8 and NaV1.9. (B) Relative expression of NaV transcripts in thoracolumbar 761 
and lumbosacral colonic sensory neurones (C) Co-expression analysis of voltage-gated sodium 762 
channels in both thoracolumbar and lumbosacral colonic sensory neuronal populations. Each 763 
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segment in the wheel-diagrams is representative of a single cell with a coloured segment 764 
signifying positive expression.  765 
 766 
Figure 6. Somatic pain behaviors and tibial nerve activity to noxious thermal stimulation in 767 
NaV1.7Nav1.8 and littermate mice. (A) Thermal pain thresholds in NaV1.7Nav1.8 mice are 768 
significantly increased following ramping hotplate behavioral testing. (B) Average thermal pain 769 
thresholds following the application of selective NaV1.7 antagonist PF-5198007 (1 or 3mg/kg) 770 
or vehicle in NaV1.7Nav1.8 and littermate mice. Example raw traces, rate histogram and 771 
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temperature recordings of tibial nerve activity in littermate (C) and NaV1.7Nav1.8 mice (D). (E) 772 
Sum firing of tibial nerve activity during focal heat stimulation in skin-nerve preparations of 773 
NaV1.7Nav1.8 and littermate mice in the presence of TTX (100nM) or vehicle (0.1% distilled H2O). 774 
####P < 0.0001, NaV1.7Nav1.8 baseline vs. littermate baseline. (F) Effect of PF-5198007 on evoked 775 
tibial nerve firing by heat stimulation in NaV1.7Nav1.8 and littermate mice. (G) Sum firing of tibial 776 
nerve activity during focal cold stimulation in skin-nerve preparations of NaV1.7Nav1.8 and 777 
littermate mice in the presence of TTX (100nM) or vehicle (0.1% distilled H2O). (H) Effect of PF-778 
5198007 on evoked tibial nerve firing by cold stimulation in NaV1.7Nav1.8 and littermate mice. *P 779 
< 0.05, **P < 0.01, ****P < 0.0001. 780 
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 781 
Figure 7. Effect of selective small-molecule antagonism of NaV1.7 in resected human appendices 782 
following repeat noxious distension. (A) Example rate histogram of appendix mesenteric nerve 783 
activity and intraluminal pressure trace following repeat ramp distension (0-60 mm Hg; 10 min 784 
interval). Application of PF-5198007 was initiated at the start of the black bar and maintained 785 
for 50 min during which distensions were continued. (B) Average firing rates to repeat ramp 786 
distension (0-60 mm Hg; N = 5) of human appendix prior to, and after, addition of PF-5198007; 787 
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neither low-threshold or high-threshold afferent firing is affected by antagonism of NaV1.7. Both 788 
change in peak firing rate (C) and total afferent firing (D; Area Under Curve) were unchanged by 789 
bath superfusion with PF-5198007 (N = 5). 790 
 791 
 792 
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